Future Focus: The industry’s top five biggest drug patent expirations in 2016
October 21, 2015Manufacturing and Production, Research and Development biosimilars, blockbuster, generics, patent cliff, patents
From Humira to Cubicin, some multi-billion dollar drugs are set to be hit hard by patent expiries next year, and …
Novartis acquires Admune Therapeutics
October 21, 2015Research and Development Admune Therapeutics, Cancer, Novartis, Palobiofarma, immunotherapy
Novartis is broadening its portfolio of cancer immunotherapies with the acquisition of Admune Therapeutics, and signing licensing agreements with Palobiofarma …
NHS research activity on the rise
October 21, 2015Research and Development
NHS England has achieved a significant increase in clinical research over the last year, according to new data from The …
Valeant announces strong Q3 results, will expand US contact lens plant
October 20, 2015Manufacturing and Production, Sales and Marketing Valeant, financial results, manufacturing, production
Valeant has announced plans to invest up to $150 million and add 200 jobs at its Bausch and Lomb plant …
‘Female Viagra’ goes on sale in the US
October 20, 2015Addyi, HSDD, Sprout, female viagra, flibanserin, hypoactive sexual desire disorder
The pill dubbed the female version of Viagra – Sprout Pharmaceuticals’ Addyi – has gone on sale in the US. …
Daiichi sheds more US jobs as generic losses take their toll
October 20, 2015Daiichi, Daiichi Sankyo, generic competition, generics, job losses, patent cliff, patents, redundancies
The Japan-based drugmaker Daiichi Sankyo is to cut up to 1,200 jobs – or about half its workforce – in …
Domainex and Imperial College London partner on heart attack treatments
October 20, 2015Research and Development Domainex cardiac arrest
Drug discovery company Domainex and Imperial College London have announced a new partnership aimed at discovering novel therapies to treat …
Synergy Vision expands global presence to meet demand in the Asia-Pacific region
October 20, 2015Medical Communications Asia-Pacific, Australia, Sydney, Synergy Vision, asia pacific, medical communcations
UK-based Synergy Vision opens a new office in Sydney, Australia, to meet the demands of their clients across the Asia-Pacific …
Recall after mislabelling of Medline Industries’ drugs
October 20, 2015Manufacturing and Production US, acetaminophen, paracetamol, product recall
Medline Industries is voluntarily carrying out a nationwide recall of the painkiller acetaminophen, due to a labelling error on the …
China’s Tianjin invests $300m in Ebola plant
October 20, 2015Manufacturing and Production China, Ebola, Ebola vaccine, manufacturing, production, vaccines
China’s Tianjin CanSino Biotechnology, a developer of affordable vaccines, says that it will invest 2 billion Yuan (£203.3 million) in …
UK ‘is the best place in the world to do big data’, says AAR lead
October 20, 2015Manufacturing and Production Accelerated Access Review, Big Data, Professor Sir John Bell
The UK is leading the world in developing new drugs from the analysis of big data, according to a leading …
Nuevolution, Johnson & Johnson begin discovery collaboration
October 19, 2015Manufacturing and Production, Research and Development Chemetics, Janssen Biotech, Nuevolution
Nuevolution and Janssen Biotech have entered into a collaboration which will use Nuevolution’s Chemetics drug discovery platform to facilitate discovery …
Regeneron to invest $350 million, create 200 jobs in Ireland
October 19, 2015Manufacturing and Production, Research and Development
US pharma company Regeneron has announced plans to invest $350 million into its production facility in Limerick, Ireland, creating 200 …
2015’s top five mergers and acquisitions in a record-breaking year
October 19, 2015Sales and Marketing Deals, acquisitions, mergers, pharma, takeovers
A new report from analysts MergerMarket reveals that mergers and acquisitions so far in 2015 have surpassed the same 2014 …
Shire’s dry eye treatment gets a no – for now
October 19, 2015Sales and Marketing Complete Response Letter, FDA, Flemming Ornskov, Shire, dry eye disease, lifitegrast
Shire has seen an application for its dry eye treatment lifitegrast rejected by the US regulator. The FDA says it …
FDA approves Boehringer’s Pradaxa reversal agent
October 19, 2015Sales and Marketing Boehringer Ingelheim, FDA, Pradaxa, Praxbind, anticoagulant, idarucizumab
The FDA has approved Boehringer Ingelheim’s Praxbind, a reversal agent for its anticoagulant Pradaxa. The US regulator approved Praxbind (idarucizumab) …
Sanofi and Regeneron heart drug Praluent available in UK
October 19, 2015Sales and Marketing Regeneron, Sanofi, alicrocumab, high cholesterol, praluent
Sanofi and Regeneron’s next-generation cholesterol-lowering treatment Praluent is now available for adult patients with high cholesterol in the UK, following …
FDA rejects AstraZeneca diabetes combination
October 16, 2015Research and Development, Sales and Marketing AstraZeneca, FDA, NDA, dapagliflozin, saxagliptin
The FDA has declined to approve AstraZeneca’s New Drug Application (NDA) for the investigational fixed-dose combination of Onglyza and and …
Pfizer’s Xeljanz denied plaque psoriasis indication by FDA
October 16, 2015Research and Development, Sales and Marketing FDA, Pfizer, Xeljanj, tofacitinib
The FDA has rejected the indication expansion of Pfizer’s Xeljanz (tofacitinib) for treatment of moderate to severe cases of plaque psoriasis. …
Top 10 US pharma advertising spenders, September 2015
October 16, 2015Medical Communications, Sales and Marketing
As a new study from TV advertising metrics company iSpot reveals the top 40 pharma companies spent $231 million on TV …
Latest content
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
